Disclaimers
This presentation provides relevant information about SoftBank Group Corp. (“SBG”) and its subsidiaries (together with SBG, the “Company”) and its affiliates (together with the Company, the “Group”) and does not constitute or form any solicitation of investment including any offer to buy or subscribe forany securities in any jurisdiction.
This presentation contains forward-looking statements, beliefs or opinions regarding the Group, such as statements about the Group’s future business, future position and results of operations, including estimates, forecasts, targets and plans for the Group. Without limitation, forward-looking statements
often include the words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “will”, “may”, “should”, “would”, “could”, “anticipates”, “estimates”, “projects” or words or terms of similar substance or the negative thereof. Any forward-looking statements in this presentation are
based on the current assumptions and beliefs of the Group in light of the information currently available to it as of the date hereof. Such forward-looking statements do not represent any guarantee by any member of the Group or its management of future performance and involve known and unknown
risks, uncertainties and other factors, including but not limited to: the success of the Group’s business model; the Group’s ability to procure funding and the effect of its funding arrangements; key person risks relating to the management team of SBG; risks relating to and affecting the Group’s investment
activities; risks relating to SB Fund (defined as below), its investments, investors and investees; risks relating to SoftBank Corp. and the success of its business; risks relating to law, regulation and regulatory regimes; risks relating to intellectual property; litigation; and other factors, any of which may cause
the Group’s actual results, performance, achievements or financial position to be materially different from any future results, performance, achievements or financial position expressed or implied by such forward-looking statements. For more information on these and other factors which may affect theGroup’s results, performance, achievements, or financial position, see “Risk Factors” on SBG’s website at https://group.softbank/en/ir/investors/management_policy/risk_factor. None of the Group nor its management gives any assurances that the expectations expressed in these forward-looking
statements will turn out to be correct, and actual results, performance, achievements or financial position could materially differ from expectations. Persons viewing this presentation should not place undue reliance on forward looking statements. The Company undertakes no obligation to update any of
the forward-looking statements contained in this presentation or any other forward-looking statements the Company may make. Past performance is not an indicator of future results and the results of the Group in this presentation may not be indicative of, and are not an estimate, forecast or projection of
the Group’s future results.
The Company does not guarantee the accuracy or completeness of information in this presentation regarding companies (including, but not limited to, those in which SB Funds have invested) other than the Group which has been quoted from public and other sources.

Regarding Trademarks
Names of companies, products and services that appear in this presentation are trademarks or registered trademarks of their respective companies.

Important Notice – Trading of SBG Common Stock, Disclaimer Regarding Unsponsored American Depository Receipts
SBG encourages anyone interested in buying or selling its common stock to do so on the Tokyo Stock Exchange, which is where its common stock is listed and primarily trades. SBG’s disclosures are not intended to facilitate trades in, and should not be relied on for decisions to trade, unsponsoredAmerican Depository Receipts (“ADRs”).
SBG has not and does not participate in, support, encourage, or otherwise consent to the creation of any unsponsored ADR programs or the issuance or trading of any ADRs issued thereunder in respect of its common stock. SBG does not represent to any ADR holder, bank or depositary institution, norshould any such person or entity form the belief, that (i) SBG has any reporting obligations within the meaning of the U.S. Securities Exchange Act of 1934 (“Exchange Act”) or (ii) SBG’s website will contain on an ongoing basis all information necessary for SBG to maintain an exemption from registering
its common stock under the Exchange Act pursuant to Rule 12g3-2(b) thereunder.
To the maximum extent permitted by applicable law, SBG and the Group disclaim any responsibility or liability to ADR holders, banks, depositary institutions, or any other entities or individuals in connection with any unsponsored ADRs representing its common stock.
The above disclaimers apply with equal force to the securities of any of the Group which are or may in the future be the subject of unsponsored ADR programs, such as SoftBank Corp. or LY Corporation.

￼2

￼3

Sadness
￼4

14 Years Ago￼52010.6.25
New 30-Year Vision

￼6

What is thesaddest thing in
life?

Death
LonelinessDespair

Excerpt from the 30-Year Vision Presentation

￼7

Causes of Death in Japan
2010
1

Malignant Neoplasm

2

Cardiovascular Disease3

Cerebrovascular Disease

4

Pneumonia

5

Traffic Accidents(Cancer)

Source: Summary of Annual Vital Statistics Monthly Report (Preliminary Figures)

￼8Causes of Death in Japan
2023年

2010
1

Malignant Neoplasm(Cancer)

1

Malignant Neoplasm

2

Cardiovascular Disease2

Cardiovascular Disease3

Cerebrovascular Disease3

Die of old age

4

Pneumonia

4

Cerebrovascular Disease5

Traffic Accidents

5

Pneumonia(Cancer)

Cancer is always a cause of sorrow for many.
Source: Summary of Annual Vital Statistics Monthly Report (Preliminary Figures)

￼9The Emotional
Pain of Families

￼1014 Years of Technological
Advancement

￼11Total Amount of Data

110ZB

Increased Data
Handling Capacity

2ZB
2010

2023
Source：International Data Corporation

￼12

CPU Processing Power
Number of Transistors Per Chip120

Accelerated
Evolution

(B)
92B

90
80B

60
54B

30

5.3B
2,250

13,4000

0.73B

3.1M

0
(Years)

’70

’80

’90

’00

’10

Based on Moore's Law, the computational processing power of CPUs is described based on the number of transistors mounted on a single chip.

’23

Source: Created by our company based on information from the websites of major chip manufacturers.

￼13

Advancement of Generative AI
Exams

GPT-4

National
Medical Exam

Accuracy Rate

Maintains the Ability
Comparable to Humans

87% (Passing: ~60%)

As-is (GPT-4) *Except Medical Licensing Exam: Simulates GPT-4 scores on each actual test item and displays the percentiles of test takers who achieved scores equivalent to those achieved on the GPT-4, (Source) OpenAI "GPT-4 Technical Report"
As-is (GPT-4) Medical Licensing Exam (USMLE): GPT-4 (5 shot)'s USMLE Sample Exam score (Source) OpenAI, Microsoft "Capabilities of GPT-4 on Medical Challenge Problems"

￼14MedicalAI￼15

Alleviate Sorrow from Illness

￼16

￼17

Establish a JV in Japan
￼18

￼19

￼20

TEMPUSRealizing Precision Medicine
through Medical Data × AI

Eric Lefkofsky

CEO

Eric Lefkofsky

Founded2015

Headquarters

Chicago, USA

Valuation$4.5B(Listed on NASDAQ)

Revenue$531.8M(Groupon Founder)(Fiscal Year Ending December 2023)
Valuation is as of June 26, 2024.

￼21

1

Genomic
Testing2

Medical Data
Aggregation & Analysis

3

AI Insights andTherapy Selection

Offering three services
￼22

What is Cancer?
Normal Cells

Cancer Cells
Genetic
Mutation

A disease caused by genetic mutations
￼23

1. Genomic Testing
Sample Collection

Patient A・・・

Patient B
Patient C
Lung cancer patients￼24

1. Genomic Testing
Sample Collection

Patient A

Genomic Analysis
Lung Cancer A

GGG CGG GCC
・・・

Patient B

Lung Cancer B

GCT TGT GGC

Patient C

Lung Cancer C

ACA GAG AAA

Lung cancer patients

Each cancer has different mutations
￼25

1. Genomic Testing
Sample Collection

Patient A

Genomic Analysis
Lung Cancer A

GGG CGG GCC
・・・

Patient B

Lung Cancer B

GCT TGT GGC

Patient C

Lung Cancer C

ACA GAG AAA

Lung cancer patients

Each cancer has different mutations

In depth understanding of cancer characteristics

￼26

2. Medical Data Aggregation & Analysis
Clinical Data

Genomic Data

Pathology Data

Imaging Data

Combining data is key to analysis

￼27

2. Medical Data Aggregation & Analysis
2,000 Hospitals
Clinical
Data

Medical
Data

Genomic
Data

Adaptor
Pathology
Data

Imaging
Data

TEMPUSAI
Database

Cleansed
Data

Real-time integration of medical information from hospitals
￼28

3. AI Insights and Therapy Selection
Medical Data
Clinical
Data

Pathology
Data

Genomic
Data

Imaging
Data

Personalized Therapy

AI

Drug A
Drug B
Drug C

Presenting optimal therapy options
￼29

3. AI Insights and Therapy Selection
Optimal Trial
Suggestion

Medical Data
Clinical
Data

Pathology
Data

Genomic
Data

Imaging
Data

AI

Clinical Trial A
Clinical Trial B
Clinical Trial C

Broader opportunities for patients
￼30

Patients presented with Clinical Trial Option
96%

3x

U.S. Average

27%

U.S. Average(Reference)

Next-Generation genomic testing+ Clinical data

(Source) N. Beaubier, et al. Nat Biotechnol. 2019
Number of surveyed patients in “Next-Generation Genomic Testing + Clinical Data”: 500 who underwent Tempus genomic testing

￼31

Number of Cancer
Patient Records

7.7

millionNumber of
Hospitals

2,000
hospitals

Number of
Data Records
Imaging
Data

1M

Pathology
Data

0.97M

DNA+RNA

0.22M

The largest medical dataset in the industry
Quoted from Tempusʼs materials

￼32Competitive Comparison (Number of Data Types)
TEMPUS

EHR

3Company A

Company B

2Company C

2Company D

42

Wide Variety ofData Types(Clinical, Genome, Pathology, Imaging Data)
SBG's own research. The numbers indicate the number of types of data available for each company.

￼33

Competitive Comparison (Data Volume)
7.7M

TEMPUS

5.7M

Company A

Company B

0.65M

Company C

0.50M

Company D

0.35M

Leading
Data Volume
SBG's own research. Tempus data as of March 31, 2024.

￼34

Academic Hospitals

65%

Oncologists

50%

Compelling market share in the U.S. Market
Quoted from Tempus’s materials, as of March 31, 2024.

￼35

TEMPUS CEO

Eric Lefkofsky
Greeting
￼36Introduction to Tempus

Healthcare data has historically been siloed and unstructured,making it difficult to deploy new technologies and deliver
therapeutically relevant insights to physiciansCloud Data Storage/Computing

Our Platform

Low-Cost Molecular Profiling(parallel genomic sequencing)
Imaging & Language Technologies(NLP/OCR/LLMs)

Tempus is focused on building the leading AI-enabled(Intelligent) Diagnostic platform in the world, by integrating

Data + Diagnostics

￼42

Providers

Life Sciences
ML

TempusOperating
System
AI

Data Ingestion & Acquisition

State of the art highthroughput testing labs
DNA

RNA

Proteomics

Multi-modal data from trusted
healthcare institutions and associations
Longitudinal Clinical Data

Clinical Imaging

Pathology

The Cancer
Genome Atlas
10,000
DNA+RNAWe operate at scale~7,700,000
clinical records

We are connected to >65% of all
Academic Medical Centers and>50% of oncologists in the U.S. areconnected through our sequencing
and data collection efforts.

>1,000,000
imaging records

The Cancer
Genome Atlas
10,000
DNA+RNA>970,000
samples sequenced>220,000
DNA +RNA
profilesMOLECULAR REPORTS

Key findings and treatments
for each patient, streamlined
into a clinician’s workflow.

CLINICAL TRIALS

Patient profiles update in realtime to highlight relevant,open, and recruiting clinical
trials that fit the patient’s
clinical and molecular profile.

TIME ON TREATMENT

Combines clinical, molecular,
treatment and outcomes data toderive insights for an individual
patient in the context of othersimilar patients.

LENS

Our Lens application provides
access to robust data used toderive meaningful insights onpatient populations, treatment
pathways and outcomes.

The joint venture allows Tempus to build clinical sequencing capabilities,
organize patient data, and build a real-world data business in Japan.
Tempus and the joint venture have entered into technology and data licenses
to enable the joint venture’s operations—the first of its kind for Tempus

GENOMICS
Diagnostic Testing

ANALYTICSDATA & SERVICES
Licensing &Analytical Tools

DIAGNOSTICS

APPLICATIONSAI APPLICATIONSTherapy &Trial Matching

GENOMICS
Diagnostic TestingOur first product line, Genomics,
focuses on delivering intelligent
and personalized molecular results
to physicians

Companion Dx

Tempus xT CDx 648 gene solid tumor cancer CDx assay*
Tempus xR IVD Whole transcriptome RNA assay

Genomics

Tempus xT 648 gene solid tumor assay
Tempus xR Whole transcriptome RNA sequencing panel
Tempus xF, xF+ 105 & 523 gene liquid biopsy cancer assays
Tempus xE Whole exome cancer assay
Tempus xG, xG+ 36 & 77 gene inherited cancer risk germline assays
Tempus xM MRD Tumor-naïve MRD assay
Tempus xM NeXT Tumor-informed WGS MRD assay
Tempus xM Monitor Tumor-naïve ctDNA detection and quantification (RUO Only)

PGx

DPYD Dihydropyrimidine dehydrogenase deficiency
UGT1A1 UDP Glucuronosyl - transferase deficiency
nP Pharmacogenomic profiling in neuropsychiatry

AI algorithms

HRD Homologous recombination deficiency
TO Tumor Origin—predicts cancer histology and site

Ancillary tests

HER2 Protein Expression**
FOLR1 FRɑ expression
MMR Mismatch Repair Proteins
PD-L1 PD-L1 22C3, PD-L1 28-8, PD-L1 SP142

TESTS

Our tests are developedwith scientific rigor.

xM
Tempus’ growth to date in Genomics has been entirely within treatment selection.
With our MRD assay, we gain access to a significantly larger global market opportunity.

EARLY STAGE

Detection

Dx

Neoadjuvant

LATE STAGE

Surveillancemonitoring

Treatment
selection

Treatment response monitoringxM

xT CDxxM

xM (Next Personal Dx)xTxM (Next Personal Dx)

Adjuvant
treatment

xG/xG+xR
Curative intent procedure
ctDNA

xF/xF+
xE
xG/xG+Time

GENOMICS
Diagnostic Testing

ANALYTICSDATA & SERVICES
Licensing &Analytical Tools

DIAGNOSTICS

APPLICATIONSAI APPLICATIONSTherapy &Trial Matching

DATA & SERVICES
Licensing &Analytical Tools

LICENSE DE-IDENTIFIED DATA

We provide a suite of analytic
and cloud-and-compute tools topharmaceutical andbiotechnology companies.

PRECLINICAL DISCOVERYTARGET POPULATION OPTIMIZATION

CLINICAL TRIAL DESIGNGENOMICS
Diagnostic Testing

ANALYTICSDATA & SERVICES
Licensing &Analytical Tools

DIAGNOSTICS

APPLICATIONSAI APPLICATIONSTherapy &Trial Matching

AI APPLICATIONSTherapy &Trial Matching

TRIAL MATCHING
Our algorithms look at multimodal data and make AI-enabled diagnostic
recommendations only possible by virtue of our connectivity to providers.

6-12 months
Industry average: Activation initiation
to patient consent~14 days
Tempus: Activation initiated toactivation complete

3-10 days
Tempus: Average from site activation
to patient consent

Signed & active

In onboarding

Patient reported outcomes
ONCOLOGY
Use molecular data to help identify primarylocation of tumor when its unknown, flag if
a patient is HRD+

Clinical data from EHR systems
ML

Radiology images & reports

TempusOperating
SystemGermline & molecular data

CARDIOLOGY
Use ECG data to screen for
undiagnosed AFIB or structural heartdiseaseECG & other cardiology dataAI

Pathology slides
3rd part data, claims

RADIOLOGY
Use DICOM files to flag suspectedpulmonary lesions that are cancerous,
measure RECIST

ML

TempusOperating
SystemAI

ONCOLOGYNEUROPSYCHOLOGYRADIOLOGYCARDIOLOGY

We started in oncology, where we have proven and scaled the model.
With each new disease area, we expand upon the model by developing
Intelligent Diagnostics to advance patient care and accelerate drug
discovery and development.

￼67

￼68

Patients Who Receive Genomic Testing30%

1/30 x・・・

In Japan, fewer patients haveaccess to genomic testing
1%
U.S.

Japan
The genetic testing implementation rates in Japan and the United States：Number of tests conducted per year / Total number of patients over three years
The figures are according to Tempus AI research(Tempus AI assumes that the treatment cycle for cancer patients is every three years)

￼69

Patients can only undergo genomic testing after
exhausting standard options
1 million/year

20,000/year

CancerPatients

Standard Treatment

Personalized
Medicine

Surgery

Radiation Therapy

Genomic Testing

Combination Therapy

Post-Test
Treatment

Diagnosis
Drug Therapy(Including patients who do notneed genomic testing)

Most cancer patients start treatment without undergoing genomic testing
According to our independent investigation

￼70

The ideal state Japan should aim forCancer Patients

Choice ofTreatment
Genomic
TestingDiagnosis

orStandard
Treatment

Data Analysis

Personalized
Treatment

Genomic Data

Surgery

Clinical Data

Radiation Therapy

Pathology Data

Drug Therapy

Imaging Data

Combination Therapy

Providing personalized medicine tailored to each individual patient

￼71

Patients Who Receive Genomic Testing
30%

30%

Aiming for the Same
Level as the U.S.
1%
U.S.

Japan
The genetic testing implementation rates in Japan and the United States：Number of tests conducted per year / Total number of patients over three years
The figures are according to Tempus AI research(Tempus AI assumes that the treatment cycle for cancer patients is every three years)

￼72

1

Genomic
Testing2

Medical Data
Aggregation & Analysis

3

AI Insights andTherapy Selection

Launching services in Japan within the year
￼73

Investment
Ratio

50%

50%

CompanyName

SB TEMPUS

Start of
Operations

August 1, 2024

Capital30 Billion Yen(Tentative)(Including Capital Reserve)

￼74

U.S.

Japan

Genomic
Testing
Data Aggregation& Analysis

AI Insights andTherapy Selection

Bringing U.S.’s data-driven medical revolution to Japan

￼75

The ideal state Japan should aim forJapanese Hospitals
Clinical
Data

Medical
Data

Genomic
Data

Adaptor
Pathology
Data

Imaging
Data

TEMPUSAI
Database

Cleansed
Data

Real-time integration of medical information from hospitals
￼76

Government

BiotechVenturesPharmaHospitals

Insurance
Company

Clinics
Medical Device
Manufacturers

A strong alliance uniting the wisdom of the industry
￼77

Together with Healthcare Professionals

￼78

Artificial Super Intelligence

10,000x of human wisdom
￼79

Medical￼80

with human wisdom and ASI

Driving Down
Incurable Diseases

￼81with human wisdom and ASI

A Life Without
Health Issues

￼82with human wisdom and ASI

Staying Healthy
at Any Age

￼83Alleviate Sorrow from Illness

￼84

Information Revolution— Happiness for everyone

￼85